WuXi deepens its genomics might with Illumina, Pacific Biomarkers deals

Fresh off scoring U.S. certification for its genomics lab, China's WuXi PharmaTech is amping up its lab testing services, buying into Illumina's $1,000 genome technology and teaming up with Pacific Biomarkers to broaden its assay menu.

Clinipace dives into Asia with Choice Pharma buyout

North Carolina's Clinipace is looking to scale up its global presence, buying out Hong Kong CRO Choice Pharma and planning to merge its operations into a transcontinental player.

Quintiles' bankrollers eye another $1B in second offering

Quintiles founder Dennis Gillings and a trio of private equity backers hauled in more than $400 million when the company first went public, and now they're looking to reap nearly $1 billion more in a secondary public offering.

Columbia Labs inches forward in its first quarter as a CRO

After numerous setbacks and transitional moves, Columbia Laboratories has settled into its new identity as a CRO, closing its first full quarter of CRO revenue and plotting a brighter future.

INC buys its way into the Middle East with MEK deal

INC Research is doubling down on the Middle East, buying up a longtime partner to tighten its grip on a region the CRO says is rapidly developing into a go-to market for clinical research.

WuXi soars on manufacturing and plots another leap in 2014

WuXi PharmaTech boosted its revenue 15.6% last year, and China's largest CRO is expecting to match that growth in the new year, counting on steady demand for manufacturing and a larger share of the U.S. research market.

Celerion stretches into South Korea for translational studies

Early-phase CRO Celerion is expanding its reach into South Korea, partnering up with a local hospital to run trials in the country's fast-growing market for clinical research.

Harlan partners up for early-stage drug development

Indiana's Harlan Laboratories has struck up a deal with French CRO Bertin Pharma to pool resources on early development, teaming up to offer drug discovery and translational medicine services.

Charles River looks to Exostar for cloud-based data platform

CRO Charles River Laboratories has selected Exostar to serve as the gatekeeper to its data, tasking the cloud-based service provider with securing its proprietary information.

Cardialysis taps AG Mednet to handle an ocean of trial data

Netherlands' CRO Cardialysis has reached out to Boston eClinical outfit AG Mednet to oversee data submission and collection for the medical device and drug trials it runs at more than 1200 sites around the world.

Report: VC giant Sequoia unloading $50M stake in India's GVK

Indian CRO GVK Biosciences has become a global player since Sequoia Capital first bought a stake back in 2007, and now the venture capital stalwart is looking to sell its share at more than three times the price, according to The Economic Times.

MPI's imaging team-up snags a cyclotron as it preps for opening day

MPI Research and its CRO partners are a couple months away from cutting the ribbon on their imaging-focused collaboration, and now the three have installed the particle accelerator they say they'll need to stand out among other drug researchers.

Quintiles touts its talent as cash rolls in

In the CRO world, the fight to secure contracts and strategic partnerships often comes down to expertise, and Quintiles, the industry's largest outfit, believes it has a serious competitive advantage. The North Carolina CRO said it employs twice as many M.D.s and Ph.D.s as any of its competitors, giving it a leg up in the changing world of science.

InVentiv amps up its biosimilar efforts with latest deal

As demand for biosimilar development swells around the world, CRO inVentiv Health has teamed up with Australia's Proteomics International to expand its characterization services, an effort to boost its capabilities in early work on biologic knockoffs.

Charles River amps up its biologics testing

Charles River Laboratories is kicking off an all-encompassing service that will allow its biotech and pharma clients to hand over their quality-control testing for biologics en masse, a method the preclinical CRO says can save time and money.

Medpace changes hands for $915M as private equity smiles on CROs

European private equity outfit Cinven has stepped up to buy the majority of long-rumored target Medpace, trading $915 million for an undisclosed controlling stake in the CRO.

PPD partners up to give Germany a starring role in clinical trials

PPD has signed a deal with a German hospital to help bring more clinical trials to the country, agreeing to lend its global reach and help lure drug developers.

Quintiles lends its sequencing skills to massive cardiovascular study

Global Genomics Group is in the midst of an expansive cardiovascular study with hopes of finding new biomarkers and drug targets for coronary artery disease, and now the company has enlisted the help of CRO giant Quintiles to handle some of the necessary gene sequencing work.

Parexel expands its regulatory reach with latest move

Global CRO Parexel International is looking to expand its regulatory consulting, launching a dedicated unit focused on the post-approval needs of drug and medical device developers.

After soaring 20% in 2013, Icon eyes a bigger share of the CRO market

Icon watched its revenue swell by 20% last year, and now the Irish CRO is expecting a healthy rate of new business wins to fuel growth in 2014.